Company Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds.
The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma.
Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
| Country | United States |
| Founded | 2008 |
| IPO Date | Nov 6, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 325 |
| CEO | Richard A. Paulson M.B.A. |
Contact Details
Address: 85 Wells Avenue, Second Floor Newton, Massachusetts 02459 United States | |
| Phone | 617-658-0600 |
| Website | karyopharm.com |
Stock Details
| Ticker Symbol | KPTI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001503802 |
| CUSIP Number | 48576U106 |
| ISIN Number | US48576U1060 |
| Employer ID | 26-3931704 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard A. Paulson M.B.A. | President, Chief Executive Officer and Director |
| Dr. Sharon Shacham M.B.A., Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Michael P. Mason CPA, M.B.A. | Executive Vice President, Chief Financial Officer and Treasurer |
| Michael J. Mano J.D. | Senior Vice President, General Counsel and Secretary |
| Sohanya Cheng M.B.A. | Executive Vice President and Chief Commercial Officer |
| Stuart Poulton | Executive Vice President and Chief Development Officer |
| Dr. Mansoor Raza Mirza M.D. | Clinical Consultant, Member of Scientific Advisory Board and Independent Director |
| Cameron Peters | Vice President of Finance, Assistant Treasurer and Principal Accounting Officer |
| Elhan Webb C.F.A. | Senior Vice President of Investor Relations |
| James Accumanno J.D. | Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | ARS | Filing |
| Apr 19, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 19, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2024 | SC TO-C | Filing |
| Apr 8, 2024 | PRE 14A | Other preliminary proxy statements |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 20, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |